SavedAdd your journal

Journals / EMU Journal of Pharmaceutical Sciences / 2019 / Cilt: 2 - Sayı: 1

ANALGESIC NEPHROPATHY

Gönül ŞAHİN
Sonia SANAJOU
Hananeh KORDBACHEH
Pages
55–67
Publication Date
2019-09-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The geriatric group which is the most vulnerable group to misusage of NSAIDs should be well informed and monitored by healthcare professionals to decrease the risk of adverse effects related to NSAIDs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Non-steroidal anti-inflammatory drugs (NSAIDs), which are easily accessible, inexpensive and have many therapeutic effects, are used frequently and in large quantities by every age group of patients.
📊
Key Findings & Data:NSAIDs reversibly inhibit cyclooxygenase enzymes at various degrees and they have the same action and toxicity mechanism.
💡
Conclusion & Impact:The geriatric group which is the most vulnerable group to misusage of NSAIDs should be well informed and monitored by healthcare professionals to decrease the risk of adverse effects related to NSAIDs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Analgesic · Analgesic Nephropathy · cortical tubulointerstitial nephritis

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs), which are easily accessible, inexpensive and have many therapeutic effects, are used frequently and in large quantities by every age group of patients. NSAIDs reversibly inhibit cyclooxygenase enzymes at various degrees and they have the same action and toxicity mechanism. These groups of drugs can cause damage in many organs when there used at high dose and for a long-time period. Analgesic nephropathy is one of the prominent side effects of NSAIDs which damage kidneys. The present review focused on renal toxic mechanisms induced by NSAIDs. The geriatric group which is the most vulnerable group to misusage of NSAIDs should be well informed and monitored by healthcare professionals to decrease the risk of adverse effects related to NSAIDs.

🔖

Cite This Article

ŞAHİN, G., SANAJOU, S., KORDBACHEH, H. (2019). ANALGESIC NEPHROPATHY. EMU Journal of Pharmaceutical Sciences, Cilt: 2 - Sayı: 1, 55–67. https://ajindex.com/articles/829632

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, Knaggs R, Martin D, Sampson L, Schofield P, British Geriatric Society (2013). Guidance on the management of pain in older people. Age Ageing 42:1–57. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009). Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331–1346.
  2. Bluemle LW Jr, Goldberg M (1969). Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse. J Clin Invest 47(11):2507–2514.
  3. Borda IT, Koff RS (1992). In: NSAIDs: A profile of adverse effects. Philadelphia: Hanley & Belfus;. pp. 240-256.
  4. Buer JK. (2014). Origins and impact of the term ‘NSAID’. Inflammopharmacology 22(5):263–267.
  5. Chang S, Mathew T, McDonald S (2008). Analgesic nephrop- athy and renal replacement therapy in Australia: Trends, comorbidities and outcomes. Clin J Am Soc Nephrol 3:768–776.
  6. Cove-Smith JR (1981). Analgesic nephropathy in the United Kingdom: incidence, clinical features and pathogenesis. J Clin Pathol 34:1255–1260.
  7. DeWitt DL, Meade EA, Smith WL (1993). PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 95(2):40–44.
  8. De Broe M, Elseviers M (2009). Over the counter analgesic use. J Am Soc Nephrol 20:2098–2103.
  9. De Broe Marc E, Elseviers Momique M (1998). Analgesic nephropathy. N Engl J Med 338:446–452.
  10. Dunn MJ, Scharschmidt L, Zambraski E (1984). Mechanisms of the nephrotoxicity of non-steroidal anti-inflammatory drugs. Archives of Toxicology. Supplement. Arch Toxicol Suppl 7:328–337.
  11. Emkey RD, Mills JA (1982). Aspirin and Analgesic Nephropathy. JAMA 247(1):55. Fischer S, Weber PC (1984). Prostaglandin l3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307:165-8.
  12. Gault M, Wilson D (1978). Analgesic nephropathy in Canada: Clinical syndrome, management and outcome. Kidney Int 13:58–63.
  13. Hao CM, Yull F, Blackwell T, Kömhoff M, Davis LS, Breyer MD (2000). Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 106:973–982.
  14. Harris RC (2003). Interactions between COX-2 and the renin-angiotensin system in the kidney. Acta Physiol Scand 177:423-427.
  15. Harirforoosh S, Jamali F (2009). Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 8(6):669–681.
  16. Hanna VS, Hafez EAA (2018). Synopsis of arachidonic acid metabo